1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Chronic Smell and Flavor Loss Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Chronic Smell and Flavor Loss Treatment Market, by Treatment Modality
8.1.1 Smell-Training
8.1.1.1. Market Revenue and Forecast
8.1.2. Pharmacological Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. Device-Based Therapies
8.1.3.1. Market Revenue and Forecast
8.1.4. Nutritional & Dietary Supplements
8.1.4.1. Market Revenue and Forecast
8.1.5. Emerging & Adjunctive Therapies
8.1.5.1. Market Revenue and Forecast
9.1. Chronic Smell and Flavor Loss Treatment Market, by Indication
9.1.1. Postâ€viral Olfactory Dysfunction (e.g., post-COVID-19)
9.1.1.1. Market Revenue and Forecast
9.1.2. Postâ€traumatic (head injury)
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurodegenerative Disease–associated (Parkinson’s, Alzheimer’s)
9.1.3.1. Market Revenue and Forecast
9.1.4. Sinonasal Disease–related (chronic rhinosinusitis, nasal polyps)
9.1.4.1. Market Revenue and Forecast
9.1.5. Idiopathic / Other Causes
9.1.5.1. Market Revenue and Forecast
10.1. Chronic Smell and Flavor Loss Treatment Market, by End User
10.1.1. Hospitals & ENT Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Specialty Olfactory Rehabilitation Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Home-Care / Direct-to-Consumer
10.1.3.1. Market Revenue and Forecast
10.1.4. Research Institutes & Academic Centers
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment Modality
11.1.2. Market Revenue and Forecast, by Indication
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Treatment Modality
11.1.4.2. Market Revenue and Forecast, by Indication
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Treatment Modality
11.1.5.2. Market Revenue and Forecast, by Indication
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment Modality
11.2.2. Market Revenue and Forecast, by Indication
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Treatment Modality
11.2.4.2. Market Revenue and Forecast, by Indication
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Treatment Modality
11.2.5.2. Market Revenue and Forecast, by Indication
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Treatment Modality
11.2.6.2. Market Revenue and Forecast, by Indication
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Treatment Modality
11.2.7.2. Market Revenue and Forecast, by Indication
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment Modality
11.3.2. Market Revenue and Forecast, by Indication
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Treatment Modality
11.3.4.2. Market Revenue and Forecast, by Indication
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Treatment Modality
11.3.5.2. Market Revenue and Forecast, by Indication
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Treatment Modality
11.3.6.2. Market Revenue and Forecast, by Indication
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Treatment Modality
11.3.7.2. Market Revenue and Forecast, by Indication
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment Modality
11.4.2. Market Revenue and Forecast, by Indication
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Treatment Modality
11.4.4.2. Market Revenue and Forecast, by Indication
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Treatment Modality
11.4.5.2. Market Revenue and Forecast, by Indication
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Treatment Modality
11.4.6.2. Market Revenue and Forecast, by Indication
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Treatment Modality
11.4.7.2. Market Revenue and Forecast, by Indication
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment Modality
11.5.2. Market Revenue and Forecast, by Indication
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Treatment Modality
11.5.4.2. Market Revenue and Forecast, by Indication
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Treatment Modality
11.5.5.2. Market Revenue and Forecast, by Indication
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Cyrano Therapeutics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Johns Hopkins
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Boys Town National Research Hospitals
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. MSD Manual
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Alcon
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Stanford Medicine
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Immunome Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Siemens Healthcare Private Limited
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Omega Diagnostics Group PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. HYCOR Biomedical
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
